Roivant Sciences, the umbrella company for Vivek Ramaswamy’s series of ‘vant companies, acquired Silicon Therapeutics for $450 million in Roivant equity.
If you are not happy with the results below please do another search
50 search results for:
AstraZeneca and Amgen’s experimental drug tezepelumab reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers.
Drugmaker Eli Lilly said on Feb. 26 the U.S. government agreed to buy at least 100,000 doses of the company’s newly authorized COVID-19 dual antibody cocktail for $210 million, with doses to be delivered through March-end.
Takeda Pharmaceutical Co. agreed to sell four diabetes products in Japan to Teijin Pharma Ltd. for 133 billion yen ($1.25 billion).
A study published in JAMA suggests that treatment with vitamin C, in addition to thiamine and hydrocortisone, does not improve treatment outcomes in hospitalized patients with sepsis.
Mayor Bill de Blasio’s chief medical adviser on Feb. 25 downplayed the results of two studies suggesting that a new coronavirus variant found in New York City in November will be more resistant to vaccines now being administered.
The U.S. Food and Drug Administration on Feb. 25 approved storage and transportation of COVID-19 vaccine developed by Pfizer Inc. and German partner BioNTech SE at standard freezer temperatures for up to two weeks instead of ultra-cold conditions.
Med Ad News talked with Klick Health CEO Lori Grant and new Co-Presidents Greg Rice and Ari Schaefer about the recent appointment of Rice and Schaefer; the introduction of new business units; what clients are seeking from the company; and Klick’s work during the pandemic.
Fishawack Health, a leading commercialization partner for the life science industry, appointed former Covance CEO Deborah Keller as the new Chair of its board.
The U.S. Food and Drug Administration approved AbbVie’s biologic therapy Humira (adalimumab) as a treatment for moderate-to-severe active ulcerative colitis in children aged 5 years and older.